Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Support for Aduro’s ADU-1604
January 2018
SHARING OPTIONS:

BERKELEY, Calif.—Aduro Biotech Inc. shared preclinical data at the 32nd Annual Meeting of the Society for Immunotherapy of Cancer supporting ADU-1604, its humanized anti-CTLA-4 monoclonal antibody. In in-vitro and in-vivo studies, the candidate showed potency and the ability to inhibit tumor growth and enhance T cell-dependent antibody responses. Proof-of-concept studies in syngeneic mouse models showed that anti-CTLA-4 boosts anti-tumor activity when combined with ADU-S100, Aduro’s lead investigational STING agonist.
 
“These data from preclinical studies of ADU-1604, a novel anti-CTLA-4 product candidate derived from our proprietary B-select antibody platform, are encouraging and provide support to file an Investigational New Drug Application to advance ADU-1604 into clinical studies,” stated Dr. Andrea van Elsas, chief scientific officer of Aduro. “As a company with multiple programs and proprietary technology platforms, we are well positioned to leverage our product candidates, as monotherapies and in rational combinations, to develop new treatment options for patients in need.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.